Primary Objectives:
1. To determine the feasibility and toxicity profile of administering liposomal 9-Nitro-20-(S)-Camptothecin (L9-NC) by aerosol alone and in combination with temozolomide.
2. To determine the effectiveness of L9-NC given by aerosol in combination with temozolomide in patients with solid tumors involving the lungs.

开始日期2006-06-01

申办/合作机构

The University of Texas MD Anderson Cancer Center

NCT00113256

/ Terminated临床2/3期

Randomized Trial of Orathecin and Gemcitabine Versus Placebo and Gemcitabine in Patients With Non-Resectable Pancreatic Cancer Who Have Not Already Received Chemotherapy

Patients will be treated with gemcitabine and Orathecin (rubitecan) capsules to evaluate the current estimate of overall survival as a study endpoint prior to launching the blinded randomized phase (versus gemcitabine and placebo) of the study. Toxicity of the drug combination will also be evaluated.

开始日期2005-02-01

申办/合作机构

Astex Pharmaceuticals, Inc.

NCT00250016

/ WithdrawnN/AIIT

1102C-T. Pharmacology Study of Aerosolized Liposomal-Nitro-20 (S)-Camptothecin (L9NC) in Patients With Metastatic or Recurrent Cancer of the Endometrium. Tissue Submission for Patients With Endometrial Cancer.

The purpose of this study is to determine the amount of Aerosolized Liposomal-Nitro-20 (S)-Camptothecin (L9NC) in a patients blood and tumor.

开始日期2003-08-01

申办/合作机构

The University of New Mexico

100 项与鲁比特康相关的临床结果

登录后查看更多信息

100 项与鲁比特康相关的转化医学

登录后查看更多信息

100 项与鲁比特康相关的专利（医药）

登录后查看更多信息

204

项与鲁比特康相关的文献（医药）

2025-05-01·AQUACULTURE

A sudden drop in temperature causes an imbalance in skin mucus barrier homeostasis in grass carp (Ctenopharyngodon idella)

作者: Wu, Congdi ; Zhang, Siyu ; Cui, Subin ; Gao, Xiaoning ; Cheng, Zihao ; Zhang, Yangyang ; Chen, Rong ; Wang, Yali ; Hu, Kun

This study examined how a sudden drop in temperature affects the skin mucus barrier in grass carp.The findings indicated a reduction in the total epidermal mucous cells in grass carp, accompanied by a thinning and potential detachment of the mucus layer, in response to a sudden decrease in temperatureNotably, type II mucous cells exhibited heightened sensitivity to temperature fluctuations.Concurrently, immune-related enzyme activity within the mucus decreased.High-throughput sequencing and metabolomic anal. revealed that a sudden drop in temperature reduced the abundance and diversity of skin symbiotic bacteria, increased disease-associated pathogens, and decreased beneficial bacteria, with Nocardia increasing to 34.03% and Cetobacterium decreasing to 0.28%, increasing disease risk in grass carp.Furthermore, the sudden drop in temperature affected the metabolic state of grass carp and skin symbiotic bacteria, decreasing nucleotide sugars, nucleotide synthesis precursor, and lysine biosynthesis precursors and increasing purine catabolites, stress regulators, and tryptophan metabolites in mucus.This disturbs energy metabolic, nucleotide levels, protein and cellular structural component synthesis, and stress states, upsetting mucous layer balance.In addition, we discovered six metabolites that are sensitive to temperature changes and could serve as potential biol. indicators of temperature correlation.In summary, a sudden drop in temperature weakens the protective function of the skin mucus barrier, causing an imbalance in the microbial structure and metabolic function.This study aids in understanding the role of mucus in innate immunity and provides early warnings of danger to fish.

2024-05-01·JOURNAL OF CELLULAR AND MOLECULAR MEDICINE

Prognostic and immunotherapeutic implications of bilirubin metabolism‐associated genes in lung adenocarcinoma

Article

作者: Chen, Lin ; Ling, Xiean ; Ren, Kangqi ; Huang, Tonghai ; Li, Zeyao

Abstract:

Lung adenocarcinoma (LUAD) is a major subtype of non‐small‐cell lung cancer and accompanies high mortality rates. While the role of bilirubin metabolism in cancer is recognized, its specific impact on LUAD and patient response to immunotherapy needs to be elucidated. This study aimed to develop a prognostic signature of bilirubin metabolism‐associated genes (BMAGs) to predict outcomes and efficacy of immunotherapy in LUAD. We analysed gene expression data from The Cancer Genome Atlas (TCGA) to identify survival‐related BMAGs and construct a prognostic model in LUAD. The prognostic efficacy of our model was corroborated by employing TCGA‐LUAD and five Gene Expression Omnibus datasets, effectively stratifying patients into risk‐defined cohorts with marked disparities in survival. The BMAG signature was indeed an independent prognostic determinant, outperforming established clinical parameters. The low‐risk group exhibited a more favourable response to immunotherapy, highlighted by increased immune checkpoint expression and immune cell infiltration. Further, somatic mutation profiling differentiated the molecular landscapes of the risk categories. Our screening further identified potential drug candidates preferentially targeting the high‐risk group. Our analysis of critical BMAGs showed the tumour‐suppressive role of FBP1, highlighting its suppression in LUAD and its inhibitory effects on tumour proliferation, migration and invasion, in addition to its involvement in cell cycle and apoptosis regulation. These findings introduce a potent BMAG‐based prognostic indicator and offer valuable insights for prognostication and tailored immunotherapy in LUAD.

2024-01-05·INTERNATIONAL JOURNAL OF QUANTUM CHEMISTRY

QSAR studies of quinoline alkaloids camptothecin derivatives for prediction anticancer activity using linear and nonlinear methods

作者: Momeni Isfahani, Tahereh ; Ahmadi Sabegh, Mehdi ; Mohebbi, Shahaboddin ; Shafiei, Fatemeh

Abstract:

Quinoline alkaloid camptothecin (CPT) derivatives are compounds with a wide range of inhibitory activities and they are the basis of several groups of drugs. CPT is one of the prominent lead compounds in anticancer drug development. It inhibits DNA topoisomerase I (topo I) enzyme and has shown remarkable anticancer activity against lung, colon, rectum, ovarian, breast, and stomach cancers. Quantitative structure–activity relationship (QSAR) is basically a statistical approach correlating the response activity data with descriptors encoding chemical information. In the current research, a QSAR study was performed for modeling and predicting the anticancer activity (pIC50) of 76 CPT derivatives as an inhibitor of DNA topo I using the genetic algorithm multiple linear regression (GA‐MLR) and back propagation artificial neural network (BP‐ANN) methods. The results of this study indicate that the use of constitutional and geometrical descriptors provide good estimate for pIC50. The obtained results of statistical criteria, internal and external validation show the superiority of BP‐ANN model than GA‐MLR to predict the pIC50 values of the investigated compounds. QSAR model developed in this study can be used for design and development of novel potent CPT derivatives and for predicting their anticancer activity.

项与鲁比特康相关的新闻（医药）

2023-11-02

·研发客

转移性三阴乳腺癌一线治疗ORR 79%！Dato-DXd联用度伐利尤单抗显示持久疗效 | 新闻稿

· 第一三共和阿斯利康的datopotamab deruxtecan联合度伐利尤单抗，确认的客观缓解率达79%。· 两项3期研究正在评估datopotamab deruxtecan对三阴乳腺癌患者的治疗效果。东京和新泽西州巴斯金里奇 —— 1b/2期研究BEGONIA最新结果显示，接受datopotamab deruxtecan（Dato-DXd）联合度伐利尤单抗（队列7）治疗的患者队列，在既往未接受过治疗的晚期或转移性三阴乳腺癌（TNBC）患者中显示出持久的疗效，且在数据截止日期后的另外6个月随访中未观察到新的安全性信号。Dato-DXd是一款由第一三共和阿斯利康共同开发针对靶向TROP2的DXd抗体偶联药物（ADC）。上述结果在2023年欧洲肿瘤内科学会（ESMO23）大会的小型口头报告会议（379MO）期间发布。全世界每年约有30万人被确诊三阴性乳腺癌，这是一种最具侵袭性的乳腺癌亚型1,2。不到一半的转移性TNBC患者会在一线治疗选择化疗±免疫检查点抑制剂时产生应答反应2,3,4 。即使在对初始治疗产生应答的肿瘤患者中，疾病进展也较为常见且发展迅速，通常情况下两年内就会出现疾病进展2,4,5, 6。结果显示，Dato-DXd联合度伐利尤单抗的确认的客观缓解率（ORR）为79%（95%置信区间[CI]：67-88），包括6例完全缓解（CR）和43例部分缓解（PR）。无论PD-L1表达水平如何，均可观察到缓解。中位无进展生存期（PFS）为13.8个月（95% CI：11-不可计算 [NC]），中位缓解持续时间（DoR）为15.5个月（95% CI：9.9-NC），随访时间为11.7个月。参与本项研究的研究者Peter Schmid医学博士（Barts Cancer Institute, London, United Kingdom）说：“Dato-DXd联合度伐利尤单抗在一线治疗三阴乳腺癌的结果非常令人欣喜，客观缓解率高达79%。尤其值得注意的是，这一高应答出现在大多数患者为PD-L1低表达的队列中，而这些患者亟需更有效的治疗方案。” ”Dato-DXd联合度伐利尤单抗的安全性特征与两种药物的已知安全性特征一致。治疗期间3级或3级以上级不良事件（TEAE）的发生率为57%。最常见的3级或3级以上的TEAE为淀粉酶增加(18%)、口腔炎(11%)、便秘(2%)、疲劳(2%)、呕吐(2%)和食欲下降(2%)。3例间质性肺疾病（ILD）事件被独立委员会确定为与药物有关，其中有两例2级事件和一例1级事件。第一三共全球肿瘤临床开发部负责人Mark Rutstein医学博士说：“对于三阴乳腺癌患者来说，初始治疗后疾病进展是一个事实，他们亟需疗效更为持久的治疗选择。这些研究结果一定程度上证实了Dato-DXd对于既往未接受过治疗的晚期三阴乳腺癌患者的治疗潜力，在3期研究TROPION-Breast01取得阳性结果后，越来越多的临床证据表明这种靶向TROP2的抗体偶联药物可作为单药治疗或与其他药物联合用于多种乳腺癌亚型。” 阿斯利康首席医学事务官兼肿瘤学首席开发官Cristian Massacesi医学博士说：“多年来，一线晚期三阴乳腺癌治疗未取得较大进展，需要新的治疗策略来改善这种具有较高侵袭性乳腺癌亚型患者的预后。BEGONIA研究的最新结果加强了我们对Dato-DXd或将成为这一领域新的、重要的治疗方案的信心，同时我们也热切期待正在进行的3期三阴乳腺癌研究的结果。” ”在BEGONIA研究的列队7（n=62）中，大多数患者（n=54）的肿瘤PD-L1表达水平较低（肿瘤面积阳性率[TAP]<10%）。7例患者的肿瘤具有PD-L1高表达状态（TAP≥10%）。截至2023年2月2日数据截止日期时，29例患者（47%）仍在接受研究治疗。第一三共和阿斯利康共同开展的两项3期研究旨在TNBC患者中评价Dato-DXd的疗效。TROPION-Breast02研究旨在评估Dato-DXd相较于传统化疗用于治疗既往未接受过或不适合接受抗PD-L1疗法的局部复发、无法手术或转移性TNBC患者的疗效。TROPION-Breast03研究旨在评估Dato-DXd±度伐利尤单抗相较于研究者选择的治疗方案用于治疗新辅助治疗后有残留疾病的1~3期TNBC患者的疗效。ESMO 2023大会期间几个专题报告展示了Dato-DXd在多种肿瘤类型和疾病阶段下疗效数据的价值，包括大型3期临床研究TROPION-Lung01和TROPION-Breast01的结果。关于BEGONIA（上下滑动查看）BEGONIA 是一项开放性、两部分、多中心1b/2期试验，旨在评价联合其他疗法（含或不含紫杉醇）用于治疗转移性TNBC一线治疗的疗效和安全性。列队7评价Dato-DXd联合度伐利尤单抗治疗既往未接受过治疗的不可切除、局部晚期或转移性TNBC患者的安全性、耐受性和初步疗效。研究的主要终点为安全性和耐受性。次要终点包括研究者评估的ORR、PFS以及DoR和OS。BEGONIA研究的列队8目前正在招募受试者，该组正在评估datopotamab deruxtecan联合度伐利尤单抗治疗肿瘤为PD-L1高表达状态的TNBC患者。关于三阴乳腺癌乳腺癌是世界上最常见的癌症，也是导致癌症相关死亡的主要原因1。2020年，全球确诊的乳腺癌病例超过200万例，死亡人数近68.5万1。有些乳腺癌的雌激素受体阳性、孕激素受体阳性或人表皮生长因子受体2（HER2）过表达的检测结果可能呈阳性，而TNBC的这三项检测结果均为阴性2。三阴性乳腺癌约占所有乳腺癌的15%（每年约有30万例），是最具侵袭性的乳腺癌亚型1,2。晚期或转移性TNBC的一线治疗通常包括单独化疗或与免疫疗法联合治疗，这些治疗选择的缓解率通常在30%到50%之间2,3,4。在对初始治疗产生应答反应的肿瘤患者中，疾病进展较为常见且发展迅速，通常在两年内出现疾病进展2,4,5,6。转移性TNBC患者的平均总生存期为12至18个月，只有约12%的患者能够在确诊后存活五年。7,8TROP2是一种在包括TNBC在内的多种实体瘤中广泛表达的跨膜糖蛋白。乳腺癌患者中， TROP2表达与肿瘤进展加速和生存期较短有关。9,10关于第一三共和阿斯利康的合作第一三共与阿斯利康分别于2019年03月和2020年07月达成全球合作，共同开发并商业化优赫得®和datopotamab deruxtecan，在日本市场第一三共拥有各款ADC产品的独家权益。第一三共负责优赫得®和datopotamab deruxtecan的生产和供应。关于datopotamab deruxtecan（Dato-DXd）Dato-DXd（datopotamab deruxtecan）是一款靶向TROP2的在研抗体偶联药物（ADC）。Dato-DXd采用第一三共专有的DXd ADC技术设计，是第一三共肿瘤领域管线中的三款核心ADC之一，也是阿斯利康ADC科学平台中最先进的项目。Dato-DXd由人源化抗TROP2 IgG1单克隆抗体（与札幌医科大学合作开发）通过可裂解的四肽连接子，与拓扑异构酶I抑制剂有效载荷（喜树碱类衍生物）连接组成。目前全球正在进行一项名为TROPION的综合开发项目，其中有超过12项研究评价Dato-DXd在多种可靶向TROP2的肿瘤中的疗效和安全性，包括非小细胞肺癌（NSCLC）、TNBC和HR阳性、HER2低表达或阴性乳腺癌。除TROPION项目外，其他几项正在进行中的研究中正在评估Dato-DXd作为新型联合治疗中的疗效。关于第一三共DXd ADC产品组合第一三共DXd ADC产品组合目前主要有六款处于临床开发阶段的ADC药物，涵盖多种癌症类型。优赫得®（靶向HER2的ADC）和datopotamab deruxtecan（Dato-DXd，靶向TROP2的ADC）目前正由第一三共与阿斯利康共同开发并在全球范围内商业化。另外四款第一三共DXd ADC包括patritumab deruxtecan（HER3-DXd，靶向HER3的ADC）、ifinatamab deruxtecan（I-DXd，靶向B7-H3的ADC）、raludotatug deruxtecan（R-DXd，靶向CDH6的ADC）以及DS-3939（靶向TA-MUC1的ADC）。每款ADC均采用第一三共独有的DXd ADC技术设计，用于靶向表达特定细胞表面抗原的癌细胞，并将细胞毒性有效载荷递送至癌细胞内部。每款ADC由单克隆抗体通过可裂解四肽连接子与多个拓扑异构酶I抑制剂有效载荷（一种依喜替康衍生物，DXd）连接组成。datopotamab deruxtecan、ifinatamab deruxtecan、patritumab deruxtecan、raludotatug deruxtecan和 DS-3939均为在研药物，尚未在任何国家获批用于任何适应症。尚未完全确定安全性和疗效。关于第一三共第一三共是一家为社会可持续发展做贡献的创新型全球医疗保健公司，致力于发现、开发和提供新的标准疗法，以提高世界各地患者的生活质量。第一三共专注制药行业120余年，凭借其世界一流的科学和技术，为癌症、心血管疾病和其他医疗需求远未得到满足的疾病患者研发新的治疗方法和创新药物。如欲了解更多信息，请访问http://www.daiichisankyo.com/。参考文献：1.Sung H, et al. CA Cancer J Clin.2021;10.3322/caac.216602.O’Reilly D, et al. World J Clin Oncol 2021; 12(3):164-182. 3.Bergin A, et al. F1000Res. 2019; doi:10.12688/f1000research.188884.Zhang Y, et al. BMC Cancer. 2021; 21(568).5.Cortes J, et al. N Engl J Med. 2022; 387: 217-226. 10.1056/NEJMoa2202809.6.Emans, et al. JNCI J Natl Cancer Inst. 2021; 113(8): dja004.7.National Cancer Institute. SEER cancer stat facts: female breast cancer subtypes. Accessed October 2023.8.Sharma P, et al. Oncologist. 2016; 21(9): 1050-62. 10.1634/theoncologist.2016.0067.9.Lin H, et al. Exp Mol Pathol. 2013;94(1):73-8.10.Goldenberg D, et al. Oncotarget. 2018;9(48): 28989-29006.

临床结果临床3期抗体药物偶联物临床成功

2006-08-23

·BioSpace

Mayne Pharma Limited Completes Purchase Of SuperGen, Inc.'s North American Oncology Products; Mayne Pharma To Pay $34 Million

DUBLIN, Calif. and MELBOURNE, Australia, Aug. 23 /PRNewswire/ -- Mayne Pharma Limited (ASX: MYP - News) and SuperGen, Inc. (Nasdaq: SUPG - News) today announce that the proposed acquisition of the North American rights to SuperGen's Nipent® (pentostatin for injection) and SurfaceSafe(TM), as communicated on 22 June 2006, has completed. Mayne Pharma will pay a total maximum consideration of US$34 million inclusive of approximately US$14 million at completion. Remaining payments are contingent on key events and product performance. For further information about Mayne Pharma, please contact: Investor Contact Media Contact Andrew Rowe Teresa La Thangue Vice President Investor Relations Media Relations Manager Ph: +44 (0) 20 7420 8426 Ph: + 44 (0) 20 7420 8479 Mobile: +44 7920 598 353 Mobile: +44 7920 598 352 or Sue Cato Ph: +61 293602021 Mobile: +61 419282319 For further information about SuperGen, please contact: Timothy L Enns Sharon Weinstein SuperGen, Inc. Noonan Russo Tel: (915) 560 0100 x 111 Tel: (212) 845 4271 tenns@SuperGen.com Sharon.weinstein@eurorscg.com Notes to editors: About SuperGen Based in Dublin, California, SuperGen is a pharmaceutical company dedicated to the discovery, acquisition, rapid development and commercialization of therapies for solid tumors and hematological malignancies. SuperGen's portfolio includes Orathecin(TM) (rubitecan) capsules, an investigational drug intended for the treatment of pancreatic cancer, Nipent® (pentostatin for injection), Mitomycin, SurfaceSafe® cleaner, and a number of preclinical products being developed as inhibitors of aurora-A, tyrosine kinase and DNA methyltransferase. For more information about SuperGen, please visit . About Mayne Pharma Mayne Pharma Limited is a specialty pharmaceutical company focused on developing, manufacturing and selling a comprehensive range of products to oncology customers in more than 65 countries around the world. The company seeks to augment its growth by accessing additional marketed or development- stage products either through acquisition or partnership. Mayne Pharma generated sales of more than $US 500 million in its financial year ended 30 June 2005 and is listed on the Australian Stock Exchange under the symbol 'MYP'. For more information about Mayne Pharma, please visit . This press release contains "forward-looking" statements within the meaning of Section 21A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and is subject to the safe harbor created thereby. These forward-looking statements include statements regarding the ability of the proposed transaction to strengthen SuperGen's financial position and enable SuperGen to commercialize its other products. Such statements are just predictions and involve risks or uncertainties such that actual results and performance may differ materially. Factors that might cause such a difference include (1) the failure of the parties to consummate the proposed transaction, (2) failure by Mayne to achieve the revenue milestones, resulting in SuperGen's failure to earn the deferred payments under the agreement. These and other risks are detailed from time to time in SuperGen's periodic filings with the Securities and Exchange Commission, including the report on Form 10-K for the fiscal year ended December 31, 2005 and on Form 10-Q for the quarter ended June 30, 2006. These forward-looking statements are made only as of the date hereof, and we disclaim any obligation to update or revise the information contained in any such forward-looking statements, whether as a result of new information, future events or otherwise. Nipent® is a registered trademark of SuperGen, Inc. Source: SuperGen, Inc. >>> Discuss This Story

并购

2006-06-06

·BioSpace

SuperGen, Inc. Completes Contract To Transition Wyeth Distribution Of Nipent(R), Outside Of The U.S.

DUBLIN, Calif., June 6 /PRNewswire-FirstCall/ -- SuperGen, Inc. today announced that a contract has been executed to terminate the distribution of Nipent(R) (pentostatin for injection) by Wyeth and transition distribution to SuperGen, Inc. The Company paid Wyeth a $2.1 million dollar early termination fee, making it effective June 1, 2006. SuperGen and Wyeth will collaborate to ensure uninterrupted distribution services during the transition period. Distribution and marketing for Nipent in Europe will be managed by SuperGen's subsidiary, EuroGen Pharmaceuticals Limited, which is based in Cheltenham, United Kingdom. EuroGen will have a commercial presence at the upcoming European Hematology Association (EHA) meeting in Amsterdam, The Netherlands. Additionally Nipent will be discussed within a symposium on June 15 at EHA entitled "M.D. Anderson Cancer Center Approach to Patients with Hematological Malignancies," chaired by Michael J. Keating, M.D. About Nipent Nipent(R) (pentostatin for injection) is currently approved as a single- agent treatment for patients with Hairy Cell Leukemia in the United States and selective counties within Europe, and is not approved as either a single agent or as part of a combination regimen for treatment for any other indication in any territory. About SuperGen Based in Dublin, California, SuperGen is a pharmaceutical company dedicated to the discovery, acquisition, rapid development and commercialization of therapies for solid tumors, hematological malignancies and blood disorders. SuperGen's portfolio includes Orathecin(TM) (rubitecan) capsules, an investigational drug intended for the treatment of pancreatic cancer, Nipent(R) (pentostatin for injection), Mitomycin, and Surface Safe(R) cleaner. In addition, a number of aurora-A, tyrosine kinase and DNA methyltransferase inhibitors are under development. For more information about SuperGen, please visit . Contacts: SuperGen Noonan Russo Timothy L. Enns Sharon Weinstein S.V.P., Corporate Communications Director of Investor Relations & Business Development Tel: (925) 560-0100 x111 Tel: (212) 845-4271 E-mail: tenns@supergen.com E-mail: sharon.weinstein@eurorscg.com SuperGen, Inc. CONTACT: Timothy L. Enns S.V.P., Corporate Communications & BusinessDevelopment for SuperGen, +1-925-560-0100 x111, tenns@supergen.com; orSharon Weinstein, Director of Investor Relations of Noonan Russo forSuperGen, +1-212-845-4271, sharon.weinstein@eurorscg.com Web site:

并购合作

100 项与鲁比特康相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D04031	鲁比特康	-	DB06159

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
不能切除性胰腺癌	临床3期	美国	Astex Pharmaceuticals, Inc.	2005-02-01
胰腺腺癌	临床3期	美国	Astex Pharmaceuticals, Inc.	1999-03-01
胰腺癌	临床3期	美国	Astex Pharmaceuticals, Inc.	1998-11-01
晚期胃癌	临床2期	美国	Astex Pharmaceuticals, Inc.	2000-04-01
食管癌	临床2期	美国	Astex Pharmaceuticals, Inc.	2000-04-01
晚期结直肠腺癌	临床2期	美国	Astex Pharmaceuticals, Inc.	1999-09-01
转移性乳腺癌	临床2期	美国	Astex Pharmaceuticals, Inc.	1999-09-01
胃肠道间质瘤	临床2期	美国	Astex Pharmaceuticals, Inc.	1999-06-01
转移性软组织肉瘤	临床2期	美国	Astex Pharmaceuticals, Inc.	1999-06-01
小肠癌	临床2期	美国	Astex Pharmaceuticals, Inc.	1999-06-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


CALGB 99901 (Pubmed \| Urol Oncol)	临床2期	转移性去势抵抗性前列腺癌二线	35	9-nitrocamptothecin	膚顧醖觸鹽餘憲築醖夢(遞蓋築願憲襯窪襯鹹淵) = 製觸鏇築壓鑰蓋遞齋鑰艱鑰襯鹹築繭糧齋蓋選 (醖醖膚願鹽鏇願獵餘廠, 5 ~ 12) 更多	不佳	2004-10-31
ASCO2004	临床1期	晚期癌症	24	Rubitecan + Gemcitabine	鑰顧夢鬱餘製醖夢觸選(願鏇齋夢繭築糧壓網壓) = 壓鑰蓋糧壓齋糧蓋獵餘醖選遞顧淵襯衊獵醖鹹 (顧鏇鹽網鏇選顧鑰遞鏇 ) 更多	-	2004-07-15
ASCO2004	临床3期	胰腺癌	409	Rubitecan (ORA)	製鑰膚鏇網顧衊衊壓繭(淵衊遞鬱選齋醖夢鹽願) = 鏇築網鹹簾鹹鬱夢鑰顧製蓋壓夢夢醖獵膚觸鬱 (獵選糧夢網蓋鬱壓蓋簾 ) 更多	-	2004-07-15
ASCO2004	临床3期	胰腺癌	409	rubitecan (Best Choice (BC))	製鑰膚鏇網顧衊衊壓繭(淵衊遞鬱選齋醖夢鹽願) = 艱築網網網顧廠夢鑰獵製蓋壓夢夢醖獵膚觸鬱 (獵選糧夢網蓋鬱壓蓋簾 ) 更多	-	2004-07-15